Los ntawm Prodrug rau Active Metabolite: Vim li cas 2-Hydroxyflutamide Yog Tus Tsav Tsheb Tseem Ceeb ntawm Antiandrogen Receptor Activity
Hauv endocrine pharmacology thiab oncology, lub tswvyim "prodrug" yog lub hauv paus ntawm kev tsim tshuaj tsim nyog. Ntau tus kws kho mob qhia txog kev ua haujlwm lom neeg tsawg tsawg thaum tswj hwm thiab xav tau biotransformation hauv daim siab kom ua tiav lawv cov tshuaj pharmacological tag nrho.
Cov non-steroidal antiandrogen "flutamide" yog ib qho piv txwv classic ntawm no biochemical mechanism. Txawm hais tias dav pom nyob rau hauv cov ntaub ntawv tshawb fawb, flutamide ua haujlwm feem ntau yog ib qho khoom siv; Nws cov ntsiab lus tseem ceeb ntawm cov metabolite tsav feem ntau ntawm nws cov kev kho mob ua tau zoo thiab cov tshuaj pharmacodynamic ua-2-hydroxyflutamide (tseem hu rau hauv cov ntaub ntawv tshaj lij xws li hydroxyniphtholide lossis SCH 16423).
Nkag siab txog kev hloov pauv metabolic ntawm flutamide mus rau 2-hydroxyflutamide yog qhov tseem ceeb rau kev tuav cov androgen receptor (AR) kev taw qhia txoj hauv kev, cellular binding affinity, thiab tsim cov kev sim niaj hnub hauv vitro.
Biotransformation Pathway: Hepatic Conversion Mechanisms
Thaum nkag mus rau hauv lub cev, flutamide ua rau lub siab sai sai tshem tawm thiab enzymatic oxidation. Hepatic Phase I cytochrome P450 enzymes, tshwj xeeb tshaj yog CYP1A2 thiab CYP3A4, feem ntau catalyze no metabolic transformation.
Flutamide (prodrug) ──[hepatic CYP1A2/CYP3A4-mediated hydroxylation]──>2-hydroxyflutamide (active molecule)
Los ntawm regioselective hydroxylation ntawm qhov thib ob carbon txoj hauj lwm, lub siab tsim 2-hydroxyflutamide-ib qho kev hloov kho uas cuam tshuam cov compound cov khoom siv biochemical:
Binding Affinity: Unmodified flutamide nthuav tawm kuj tsis tshua muaj affinity rau lub nuclear androgen receptor. Tom qab hydroxylation, 2-hydroxyflutamide txoj kev khi kev sib raug zoo nce ntxiv, ua rau nws yog thawj tus neeg sawv cev tiv thaiv androgen signaling hauv cov ntaub so ntswg.
Systemic bioavailability: Tom qab kev tswj qhov ncauj ntawm niam txiv compound, plasma concentrations ntawm 2-hydroxyflutamide muaj ntau ntau dua li cov unmetabolized flutamide, tsim nws ua tus thawj tsav tsheb ntawm anti-androgenic teebmeem nyob rau hauv vivo.
Mechanism of action: Competitive antagonism ntawm qib cellular
Ntawm qib molecular, 2-hydroxyflutamide ua haujlwm raws li kev sib tw antagonist ntawm androgen receptor (AR) ligand-binding domain (LBD).
1. Kev sib tw ntawm ligands
Endogenous androgens-tshwj xeeb yog dihydrotestosterone (DHT) thiab testosterone-ib txwm khi rau androgen receptor (AR) los tsim cov ligand-receptor complexes ruaj khov . 2-hydroxyflutamide sib tw ncaj qha nrog cov ligands endogenous rau qhov chaw khi, txo qis tag nrho androgen receptor nyob.
2. Transcriptional inhibition
Thaum khi rau receptor, 2-hydroxyflutamide induces ib tug conformational kev hloov pauv uas tiv thaiv tus receptor los mus txog ib tug ruaj khov lub xeev. Yog li ntawd, androgen receptor (AR) complex tsis tuaj yeem hloov mus rau hauv lub cell nucleus los yog khi rau androgen teb cov ntsiab lus (AREs) ntawm genomic DNA. Yog li ntawd, kev hloov pauv ntawm androgen-regulated downstream noob yog inhibited zoo.
3. Accelerated receptor turnover
Cov kev tshawb fawb ntawm cov tshuaj lom neeg ntawm tes qhia tau hais tias cov complex tsim ntawm 2-hydroxyflutamide thiab androgen receptor (AR) hloov cov receptor lub neej ib nrab, ua kom cov protein ntau.
4. Cov qauv qauv ntawm Mutant Receptors
Hauv kev tshawb fawb txog biology, 2-hydroxyflutamide muab cov ntaub ntawv tseem ceeb rau kev nkag siab txog kev hloov pauv hauv cov androgen receptor's ligand-binding domain (LBD). Thaum canonical antiandrogens ua tau zoo tiv thaiv cov tsiaj qus-hom AR signaling, cov ntsiab lus kev hloov pauv-xws li qhov nthuav dav AR-T877A qhov sib txawv- tuaj yeem hloov pauv tus neeg txais kev sib khi lub hnab tshos topology. Kev tshawb fawb pom tau tias 2-hydroxyflutamide koom nrog sib txawv hydrogen-bonding network nrog amino acid residues nyob rau hauv LBD, cuam tshuam seb tus receptor xav tias muaj kev ua haujlwm lossis tsis ua haujlwm. Daim ntawv qhia cov kev sib cuam tshuam stereochemical no tso cai rau cov kws tshawb fawb los qhia txog cov txheej txheem ntawm kev kho mob theem nrab thiab tsim cov phiaj xwm tom ntej rau cov phiaj xwm nuclear receptor modulators.
Cov ntawv thov kev tshawb fawb hauv Kev Tshawb Fawb Txog Niaj Hnub No
Vim hais tias 2-hydroxyflutamide ua raws li cov ligand ncaj qha tshaj li qhov tsis muaj zog ua ntej-high-purity crystalline 2-hydroxyflutamide tau dhau los ua cov cuab yeej tseem ceeb hauv kev tshawb fawb txog lub neej thiab kev tshawb fawb biopharmaceutical.
Hauv Vitro Cell Culture thiab Androgen Receptor (AR) Kev Tshuaj Xyuas
Thaum ua cov kev sim ntawm tes (xws li cov kev ntsuam xyuas cov kab mob qog nqaij hlav hauv prostate xws li LNCaP, 22Rv1, lossis VCaP), kev siv cov prodrug flutamide tuaj yeem ua rau cov ntaub ntawv tsis ruaj khov. Qhov no yog vim cov txheej txheem kab lis kev cai ntawm tes feem ntau tsis muaj peev xwm ua haujlwm siab CYP450 enzymes los hloov flutamide rau hauv nws daim ntawv nquag ntawm tus nqi ntawm lub cev.
Los ntawm kev sib koom ua ke 2-hydroxyflutamide hmoov ncaj qha rau hauv kab lis kev cai nruab nrab, cov kws tshawb fawb tuaj yeem hla cov kauj ruam hloov pauv metabolic nkaus. Qhov no ua rau qhov ncaj qha, rov tsim dua, thiab ntsuas qhov ntsuas ntawm androgen receptor inhibition hauv ib puag ncig hauv vitro.
Receptor Mutation and Drug Resistance Analysis
Hauv kev tshawb nrhiav pathological, kev kho mob ntev ntev ntawm androgen deprivation tuaj yeem ua rau muaj kev hloov pauv hauv cov tshuaj androgen receptor gene (xws li kev kawm zoo AR-T877A hloov pauv). Hauv cov txheej txheem biology, 2-hydroxyflutamide feem ntau yog siv los ua cov ntaub ntawv siv los tshuaj xyuas seb qhov kev hloov pauv hloov li cas hloov ligand tshwj xeeb, muab kev nkag siab tseem ceeb rau kev siv tshuaj tiv thaiv.
Analytical Reference Standards
Hauv bioanalytical chemistry, 2-hydroxyflutamide feem ntau yog siv los ua cov qauv siv qib siab rau cov kua chromatography-mass spectrometry (LC-MS). Nws yog dav siv los txiav txim siab cov txiaj ntsig metabolic kom muaj nuj nqis, saib xyuas kev sib cuam tshuam ntawm cov tshuaj yeeb tshuaj, thiab tsim cov tshuaj pharmacokinetic hauv cov qauv ua ntej.
Technical Specifications thiab Handling Standards
Rau cov kws tshawb fawb hauv chav kuaj thiab cov kws kho mob biopharmaceutical siv 2-hydroxyflutamide ua cov khoom siv raw lossis cov qauv tshuaj ntsuam xyuas, kev nkag siab txog nws lub cev thiab tshuaj lom neeg tsis zoo yog qhov tseem ceeb los xyuas kom meej cov txiaj ntsig kev sim.
Solubility thiab Stability:
Solubility hauv Organic Solvents: Cov hmoov crystalline no yog soluble hauv cov kuab tshuaj organic feem ntau siv hauv kev tshuaj xyuas ntawm tes; Cov concentration ntawm 25 mg / mL lossis siab dua tuaj yeem ua tiav hauv dimethyl sulfoxide (DMSO), ethanol, thiab N, N-dimethylformamide (DMF).
Cov Txheej Txheem Cia: Khaws cov hmoov hmoov zoo rau hauv lub thawv kaw, qhuav hauv cov tub yees lossis khov, tiv thaiv lub teeb.
Kev tuav cov kev daws teeb meem: Aliquot Tshuag cov kev daws teeb meem tau npaj hauv cov kuab tshuaj organic rau hauv ib qho kev siv thiab khaws cia kom tsim nyog los tiv thaiv cov tshuaj degradation thaum kawm ntev.
Qhov tseem ceeb ntawm Metabolite-Focused Research
Kev hloov pauv ntawm flutamide rau hauv 2-hydroxyflutamide qhia txog lub hauv paus ntsiab lus hauv cov kws tshuaj niaj hnub no: cov tshuaj siv tshuaj tsis tas yuav yog cov tshuaj uas ua rau muaj kev lom zem tiag tiag. Los ntawm kev tsom mus rau kev sim siab ncaj qha ntawm 2-hydroxyflutamide, cov kws tshawb fawb txog lub neej tau txais qhov tseeb, ncaj qha-ua cov cuab yeej los txiav cov androgen receptor mechanisms thaum tshem tawm qhov tsis sib haum xeeb ntawm cov metabolic hloov pauv. Raws li kev tshawb fawb rau hauv nuclear receptor signaling txuas ntxiv mus, high-purity active metabolites tseem yog lub hauv paus rau ob qho tib si kev tshawb fawb thiab biopharmaceutical innovation.